News and Trends 14 Feb 2018 Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors …tumors that express high levels of a molecule called Membrane Type 1 Matrix Metalloproteinase (MT1-MMP). The technology was developed by Greg Winter, who founded Cambridge Antibody Technology, which discovered the… February 14, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 …Headquarters: Netherlands As biotech stock markets continued to stagnate in 2022, Argenx was one of the few biotech companies whose stock price increased. The company’s lead drug is an antibody… December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 1 Sep 2025 Blood Cancer Awareness Month: What biotech holds in store …while directly targeting the cancer cells. Domain’s antibody, DT-7012, is designed to target immunosuppression at its source. Preclinical data have shown strong selectivity for CCR8, and the company is starting… September 1, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Could COVID vaccine boosters become obsolete? …the original strain) are actually very effective in neutralizing the Delta and Omicron variants. According to our findings, the effectiveness of the first antibody, TAU-1109, in neutralizing the Omicron strain… September 7, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2021 Argenx’s Potential Blockbuster Gets FDA Nod for Autoimmune Disease …marketed as Vyvgart, is an antibody fragment drug for use in adults with generalized myasthenia gravis. The FDA’s decision represents the first successful drug approval for argenx. According to Evaluate… December 21, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2024 Is tau protein the key to defeating Alzheimer’s? Asceneuron thinks so and raises $100 million to prove it …“The majority of tau pathology, characterized by neurofibrillary tangles in Alzheimer’s disease is intracellular within neurons. This is hard to access with antibody-based treatment approaches. The development of OGA-inhibiting therapies,… July 17, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2023 New therapy for prevention and treatment of COVID-19 …vivo model. ExeVir Bio’s COVID-19 pipeline includes XVR012, a combination product of the S2-targeting single-domain antibody-based XVR013 reported in the pre-print paper, and XVR014, a bispecific single-domain-based antibody construct that… March 13, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 13 Dec 2024 Is China the future of biotech? …Chinese companies were biologics. The report notes that the number of antibody drug conjugate (ADC), bispecific antibody, and CAR-T pipelines has increased by seven, five, and four times, respectively. The… December 13, 2024 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 3 Dec 2025 Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025 …partnership – with a new global licensing agreement to develop CDR-Life’s antibody-based trispecific T-cell engager, CDR111, which also activates T cells in order to selectively target and deplete rogue B cells and… December 3, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jun 2023 Shasqi using click chemistry to target cancer …antibody drug conjugates,” said Mukul Agarwal, chief business officer at Shasqi. “The reliance on chemistry, not biology for drug activation, allows for the use of small molecules, peptides, and antibody… June 6, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 OncoResponse and Regeneron to evaluate drug combo for patients with advanced cancer …in a separate biology cohort. About OR2805 OR2805 is a fully human antibody discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy. This antibody binds… September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Mar 2025 First-ever RIPTAC enters clinic: all you need to know about this new cancer approach …antibody-drug conjugates (ADCs), which are composed of a monoclonal antibody, a cytotoxic drug – typically a chemotherapy – and a linker. But unlike ADCs, which deliver the drug specifically to… March 24, 2025 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email